# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Third Harmonic Bio (NASDAQ:THRD) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(...
Summary of Financial ResultsCash Position: Cash and cash equivalents totaled $269.1 million as of December 31, 2023. Based on t...
Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate str...
Third Harmonic Bio (NASDAQ:THRD) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of ...
-SEC Filing
Morgan Stanley analyst Michael Ulz maintains Third Harmonic Bio (NASDAQ:THRD) with a Equal-Weight and raises the price targe...
Summary of Financial Results Cash Position: Cash and cash equivalents totaled $278.1 million as of June 30, 2023. Based on the...